Live
Zydus Cadila has received final approval to market Candesartan Cilexetil and Hydrochlorothiazide tablets formulations, from the US health regulator. It is used for treating high blood pressure.
In a BSE filing Cadila Healthcare stated, “The approval by the US Food and Drug Administration (USFDA) is for multiple Candesartan Cilexetil and hydrochlorothiazide tablets of 16 mg/12.5 mg, 32 mg/12.5 mg and 32 mg/25 mg.”
Further it stated that, the product will be manufactured at the group’s formulations manufacturing facility at Moraiya, in Ahmedabad.
